BANNOCKBURN, Ill., Sept. 02, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy. Manufactured by NS Pharma, Inc., Viltepso is the first and only exon 53 skipping therapy to demonstrate an increase in dystrophin in patients as young as four years old.
Viltepso is among a growing number of chronic infusion therapies for neuromuscular disorders that Option Care Health is able to deliver to patients at home or in one of the company’s more than 125 ambulatory infusion suites across the country.
“NS Pharma selected Option Care Health as an option to distribute and administer Viltepso, which offers hope to patients with this devastating disease and their caregivers, because of our reputation of providing extraordinary care,” said Matt Deans, Senior Vice President of Business Development at Option Care Health. “Our demonstrated track record of collaboration with manufacturers to extend infusion services for new therapies to alternate treatment sites, coupled with our personalized clinical care, leads to better outcomes and higher patient satisfaction.”
DMD is an inherited progressive neurological disorder that primarily affects boys because it is located on the X chromosome (male gene). It is caused by genetic mutations that prevent the production of dystrophin, a key protein for supporting muscle health. Symptoms appear as early as two years of age and typically progresses to cardiac and respiratory muscle problems beginning in the patient’s teenage years, leading to serious, life-threatening complications.
Increasing dystrophin as much and as early as possible has become a key goal in the treatment of DMD. Viltepso received an Accelerated Approval by the Food and Drug Administration (FDA) based on an increase in dystrophin in patients with DMD who are amenable to exon 53 skipping therapy; exon 53 skipping is applicable in about 8% of the DMD population.
“We chose to include Option Care Health in our distribution network because of its commitment to providing excellent clinical care and national footprint,” said Gardner Gendron, Chief Commercial Officer at NS Pharma. “Its expertise in providing infusions for complex neuromuscular conditions, broad access to insurance networks and service in all 50 states give us the confidence that our patients will be able to receive Viltepso.”
Viltepso 的推荐剂量为 80mg/kg，由在该疾病和治疗方面经过专门培训的 Option Care Health 护士每周静脉注射一次，每次超过 60 分钟。Option Care Health 与提供者密切合作，以制定定制的患者护理计划并提供定期治疗更新。患者接受了广泛的教育，如果有疑问或需要支持，可以随时联系经验丰富的临床医师。
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is re-imagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.
About NS Pharma, Inc.
NS Pharma, Inc. 是 Nippon Shinyaku Co., Ltd. 的全资子公司。要了解更多信息，请访问 http://www.nspharma.com。NS Pharma 和 Viltepso 是 Nippon Shinyaku 集团公司的注册商标。
前瞻性声明 – 安全港
本新闻稿可能包含 1995 年《美国私人证券诉讼改革法案》安全港条款所定义的“前瞻性声明”。前瞻性声明可以用诸如“预计”、“打算”、“计划”、“相信”、“项目”、“估计”、“预期”、“可能”、“应该”、“将要”以及对未来时期的类似提法来识别。前瞻性声明的例子包括但不限于，我们可能就未来收入、未来收益、监管发展、市场发展、新产品和增长战略、整合活动以及上述任何一项对我们未来经营业绩或财务状况的影响所作的陈述。
前瞻性声明既不是历史事实，也不是对未来业绩的保证。相反，它们只是基于我们当前对公司业务的未来、未来计划和战略、预测、预期事件和趋势、经济以及其他未来条件的信念、期望和假设。由于前瞻性声明与未来相关，因此它们受到固有的不确定性、风险和情况变化的影响，这些情况难以预测，其中许多是我们无法控制的情况。我们的实际结果和财务状况可能会与前瞻性声明中的内容存在重大差异。可能导致我们的实际结果和财务状况与前瞻性声明中的陈述存在重大差异的重要因素包括但不限于：(i) 适用于我们业务模式的法律和法规的变更；(ii) 市场状况以及对我们服务和产品的接受度的变化； (iii) 诉讼结果；(iv) 一家或多家主要支付方的损失； (v) 新冠疫情的传播和影响。有关可能影响我们实际结果的风险因素的详细讨论，请参阅美国证券交易委员会 (SEC) 报告中确定的风险因素，包括但不限于我们向 SEC 提交的 10-K 报表年度报告和 10-Q 报表季度报告。